Arabic Arabic English English French French German German
dark

Research team finds new dual benefit mode of action for a drug candidate to fight COVID-19

A research team led by Prof. Stephan Ludwig, a virologist at the Institute of Virology at the University of Münster, has found a new dual attack mode of action while working on the development of a drug candidate against SARS-CoV-2 infections. This could constitute the basis for a broadly effective drug to fight COVID 19.

Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Origin of rare disease FOP rooted in muscle regeneration dysfunction

Next Post

While Omicron continues to dominate across the world, COVID-19 travel requirements remain

Related Posts
Total
0
Share